DUPIXENT CAN CONTROL
MORE THAN ONE
MEASURE OF ASTHMA
See how DUPIXENT reduced severe exacerbations, improved lung function, reduced or eliminated OCS use, and has a demonstrated safety profile.
Adults and Pediatric Patients (12+ Years)
OCS Reduction/Elimination
Only FDA-approved biologic
indicated for
OCS-dependent
asthma patients1
aThrough Week 24 with DUPIXENT 300 mg Q2W + SOC (n=64) vs placebo + SOC (n=68) (0.20 vs 1.04; rate ratio: 0.19 [95% CI: 0.07, 0.56]) (baseline blood EOS ≥300 cells/µL, DRI12544, secondary endpoint).1
b470 mL improvement at Week 52 from baseline in pre-bronchodilator FEV1 with DUPIXENT 200 mg Q2W + SOC (n=264) vs 170 mL improvement with placebo + SOC (n=148) (baseline blood EOS ≥300 cells/µL, QUEST, secondary endpoint). ~72% of the total FEV1 improvement was seen after the first dose at Week 2.1,4
c75% of patients had improved ACQ-5 (asthma control) scores with DUPIXENT 200 mg Q2W + SOC vs 67% with placebo + SOC (OR: 1.46 [95% CI: 0.90, 2.35]) (baseline blood EOS ≥300 cells/µL, QUEST, secondary endpoint).1
d71% of patients had improved AQLQ(S) (quality of life) scores with DUPIXENT 200 mg Q2W + SOC vs 55% with placebo + SOC (OR: 2.02 [95% CI: 1.24, 3.32]) (baseline blood EOS ≥300 cells/µL, QUEST, secondary endpoint).1
eACQ-5 and AQLQ(S) were assessed as secondary endpoints but were ordered after the point at which the hierarchical break occurred. Results are descriptive.3
fThe asthma development program for patients aged 12 years and older included three randomized, double-blind, placebo-controlled, parallel-group, multicenter trials (DRI12544, QUEST, and VENTURE) of 24 to 52 weeks in treatment duration, which enrolled a total of 2888 subjects.1
Children (6-11 Years)
ACQ-5, Asthma Control Questionnaire, 5-item version; AQLQ(S), Asthma Quality of Life Questionnaire, Standardized Version; EOS, eosinophils; FEV1, forced expiratory volume in 1 second; OCS, oral corticosteroid; OR, odds ratio; Q2W, once every 2 weeks; SOC, standard of care.